Lupin Resolves U.S. Patent Litigation with Astellas Pharma Through $90 Million Settlement
Indian pharmaceutical company Lupin agrees to a $90 million settlement with Astellas Pharma, ending patent litigation over mirabegron in the U.S. market
Lupin Ltd., a leading Indian pharmaceutical firm, has reached a $90 million settlement with Japan-based Astellas Pharma Inc. to resolve ongoing patent disputes concerning the U.S. rights to mirabegron, a drug used to treat overactive bladder. The agreement allows Lupin to continue marketing its generic version in the…